Table 1.
Candidate proteins for peptide vaccination in myeloid leukaemias.
| Antigenic protein | Peptides under development | HLA restriction | Clinical trials | Ref. |
|---|---|---|---|---|
| Leukaemia-specific antigens | ||||
| BCR-ABL | b3a2 fusion region 9–25 mers | HLA-A3,-11, -B-8, DR-1, -4, -11 | CML | [53–55] |
| Primary granule proteins | PR1 | A-2 | MDS, AML, CML | [72] |
| PR7 | A-2 | No | [102] | |
| PML-RARA | BCR 1–25 | DR-11 | No | [103] |
| Tumour-specific antigens | ||||
| Wilms tumour-1 | WT1-126 | A-2 | MDS, AML | [36,38] |
| WT1-235 | A-2, -24 | MDS, AML | [38,104] | |
| WT1-187 | A-2 | No | [38] | |
| WT1-37 | A-2 | No | [105] | |
| H-TERT | A-2, -3, -24 | No | [106–108] | |
| PRAME | A-2 | No | [109] | |
| BCL-2 | A-2 | No | [108] | |
| G-250 | A-2 | No | [108,110] | |
| mHags | ||||
| HA-1 protein | A-2 | No | [111] | |
| HA-2 protein | A-2 | [111] | ||
| CD33 allele | A-2 | No | [111,112] | |
| CD45 allele | A-2 | No | [113] | |
BCR–ABL: breakpoint cluster region–abelson; WT1: Wilms tumour 1; MDS: myelodysplastic syndrome; AML: acute myeloid leukaemia ; CML: chronic myeloid leukaemia; HLA: human leucocyte antigen.